Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Purpose:
Our research group has been committed to the research of remifentanil-induced hyperalgesia for a long time. In the previous study, it was found that intraoperative infusion of remifentanil (0.3ug/kg•min) >1h can lead to remifentanil-induced hyperalgesia and the incidence rate is relative high in the plain area. Due to the long-term low pressure and hypoxia of people living in plateau areas, a series of changes will occur in the respiratory and circulatory systems, and their anesthesia management needs to be adjusted accordingly. However, there is no relevant research on whether or not hyperalgesia occurs in people in plateau areas (altitude level >3000 meters). Therefore, this study hopes to compare the incidence and degree of remifentanil-induced hyperalgesia after gynecological laparoscopic surgery in plain areas and plateau areas.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sufentanil-analgesia in plain area patients | Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia in plain area patients. |
| |
| Remifentanil-analgesia in plain area patients | Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia in plain area patients. |
| |
| Sufentanil-analgesia in plateau area patients | Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia in plateau area patients. |
| |
| Remifentanil-analgesia in plateau area patients | Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia in plateau area patients. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sufentanil injection | Drug | Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mechanical Hyperalgesia Threshold on the Dominant Inner Forearm | The mechanical hyperalgesia threshold was defined as the lowest force (g) necessary to bend a Von Frey filament, which was perceived to be painful by the patient and measured by Von Frey filament after surgery | 48 hours after surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Pain Score (NRS) | The pain score at rest or after movement was evaluated by pain 11-point numerical rating scale (NRS): 0 = no pain, 10= greatest imaginable pain. | 48 hours after surgery |
| Normalized Area of Hyperalgesia Around the Incision |
Not provided
Inclusion Criteria:
Exclusion Criteria:
We selected female patients which will receive gynecological laparoscopic surgery
Patients in plateau areas are long staying residents in above 3000 meters above sea level for enrollment, while patients in plain areas are long staying residents below 1000 meters above sea level.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Guolin Wang, MD | Contact | +8618604755166 | wangguolinghad@hotmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Guolin Wang, MD | Tianjin Medical University General Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Gannan Tibetan Autonomous Prefecture People's Hospital | Hezuo | Gansu | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Remifentanil Hydrochloride | Drug | Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia |
|
|
| plain areas | Other | Patients should be long staying residents in plain areas (altitude level below 1,000 meters above sea level) |
|
| plateau areas | Other | Patients should be long staying residents in plateau areas (altitude level>3000 meters above sea level) |
|
The skin around the incision is stimulated in steps of 5 mm at intervals of 1 s starting outside of the hyperalgesic area in the direction of the incision. The distance from the incision to the first point where a'painful', 'sore' or 'sharper' feeling occurred is measured and noted. This measurement is repeated at predefined radial lines around the incision. To eliminate the variable length of incision, this length is subtracted from the longer diameter leaving four radial distances from the end and from the middle of the incision. The normalized area of hyperalgesia is calculated by summing up the areas of the remaining four triangles measured by and Von Frey filament.
| 48 hours after surgery |
| Mechanical hyperalgesia threshold around the incision | The mechanical hyperalgesia threshold was defined as the lowest force (g) necessary to bend a Von Frey filament, which was perceived to be painful by the patient and measured by Von Frey filament. | 48 hours after surgery |
| Time of First Postoperative Analgesic Requirement | First postoperative pain (NRS≥5) is initially controlled by titration of Hydromorphone. | 1 hour after surgery |
| Total Dose of First Postoperative Analgesic Requirement | First postoperative pain (NRS≥5) is initially controlled by titration of Hydromorphone. | 1 hour after surgery |
| Cumulative Hydromorphone Consumption | Each patient was administered analgesics using a PCA (Patient-controlled analgesia) pump containing Hydromorphone (200μg) in normal saline at a total volume of 100 ml after leaving PACU (Postanesthesia care unit). This device was set to deliver a basal infusion of 2 ml/h and bolus doses of 0.5 ml with a 15-min lockout period. Hydromorphone cumulative consumption is recorded 48 hours postoperatively | 48 hours after surgery |
| Occurrence of Side Effects | Occurrence of side effects: nausea, vomiting, dizziness, headache, shivering, pruritus | 48 hours after surgery |
| Tianjin Medical University General Hospital | Tianjin | 300052 | China |
|
| ID | Term |
|---|---|
| D010149 | Pain, Postoperative |
| D010146 | Pain |
| ID | Term |
|---|---|
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D017409 | Sufentanil |
| D000077208 | Remifentanil |
| ID | Term |
|---|---|
| D005283 | Fentanyl |
| D010880 | Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D011422 | Propionates |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
Not provided
Not provided